» Articles » PMID: 21143012

Full-scan Mass Spectral Evidence for 3-epi-25-hydroxyvitamin D₃ in Serum of Infants and Adults

Overview
Specialties Biochemistry
Pathology
Date 2010 Dec 15
PMID 21143012
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Since the introduction of liquid chromatography-mass spectrometry (LC/MS) for assessing vitamin D status, it has been shown that the C-3 epimer can account for a significant proportion of circulating 25-hydroxyvitamin D₃ (25OHD₃) concentrations in infants. However, some question whether monitoring a single MS transition at a chromatographic retention time typical for 3-epi-25OHD₃ sufficiently warrants conclusions about the identity of the substance generating the signal. Therefore, we aimed to substantiate the evidence for 3-epi-25OHD₃ in infants by collision induced dissociation (CID)-MS/MS product ion scans. A second objective was mass spectrometric investigation of the presence and prevalence of the 3-epi metabolite in serum from adults.

Methods: Serum samples from six infants and 32 adults were studied using an ultra performance LC/tandem MS (UPLC/MS/MS) method designed to separate the 3-epi-25OHD₃ from 25OHD₃. Samples were submitted to liquid/liquid extraction and Sephadex LH-20 fractionation, prior to column-switching UPLC with MS/MS recording of CID product ion spectra of the [M+H](+) precursor ion. The respective standards were analyzed under identical UPLC/MS/MS conditions for comparison.

Results: In the chromatograms of all samples, two peaks eluted with retention characteristics and spectra closely matching those observed for the 25OHD₃ and the 3-epi standards. The percentage of the 3-epi metabolite relative to 25OHD₃ in infants ranged from 15% to 41%, and in adults from 2.5% to 17%.

Conclusions: This preliminary finding suggests that the prevalence of 3-epi-25OHD₃ in serum of infants is considerable, and that even in adults the concentrations of this form should not be neglected.

Citing Articles

Evolution and impact of Standard Reference Materials (SRMs) for determining vitamin D metabolites.

Wise S, Kuszak A, Camara J Anal Bioanal Chem. 2024; 416(9):2335-2358.

PMID: 38236394 DOI: 10.1007/s00216-024-05143-w.


Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients.

Kimsa-Furdzik M, Bednarek A, Hibner G, Czajka-Francuz P, Cison-Jurek S, Karawasiecka D Metabolites. 2023; 13(9).

PMID: 37755276 PMC: 10534610. DOI: 10.3390/metabo13090996.


Vitamin D: marker, measurand & measurement.

Dirks N, Cavalier E, Heijboer A Endocr Connect. 2023; 12(4).

PMID: 36688810 PMC: 10083657. DOI: 10.1530/EC-22-0269.


Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein - A position paper from the IFCC Committee on bone metabolism.

Makris K, Bhattoa H, Cavalier E, Phinney K, Sempos C, Ulmer C Clin Chim Acta. 2021; 517:171-197.

PMID: 33713690 PMC: 8080555. DOI: 10.1016/j.cca.2021.03.002.


Update of the tolerable upper intake level for vitamin D for infants.

Turck D, Bresson J, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M EFSA J. 2020; 16(8):e05365.

PMID: 32626014 PMC: 7009676. DOI: 10.2903/j.efsa.2018.5365.